Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics
SLRX Price/Volume Stats
| Current price | $0.50 | 52-week high | $2.31 |
| Prev. close | $0.51 | 52-week low | $0.43 |
| Day low | $0.50 | Volume | 18,069 |
| Day high | $0.52 | Avg. volume | 99,426 |
| 50-day MA | $0.57 | Dividend yield | N/A |
| 200-day MA | $0.70 | Market Cap | 2.16M |
SLRX Stock Price Chart Interactive Chart >
Salarius Pharmaceuticals Inc (SLRX) Company Bio
Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.
Latest SLRX News From Around the Web
Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.
SLRX Continues Work as it Seeks AlternativesBy Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Earnings Update • Salarius (NASDAQ:SLRX) announced a 3Q loss of $0.65 per share, compared to a $6.41 per share loss in the same quarter in 2022. • Cash and cash equivalents were $7.6 million at the end of 3Q, compared to $12.1 million at the end of 2022. Update Salarius Pharmaceuticals recently announced that it was exploring |
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramFDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities were identified; Salarius intends to submit an amended Ewing sarcoma clinical trial protocol HOUSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with th |
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateFDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new |
SLRX Pursuing Strategic AlternativesBy Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Salarius Pharmaceuticals (NASDAQ:SLRX) recently announced that it was exploring “strategic alternatives” and cutting costs in order to extend its resources. We are disappointed in this announcement as we continue to believe in the science behind the treatments being developed by Salarius. However, we understand that funding has |
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesHOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. “The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review o |
SLRX Price Returns
| 1-mo | -19.35% |
| 3-mo | -12.13% |
| 6-mo | -32.43% |
| 1-year | -71.10% |
| 3-year | -98.36% |
| 5-year | -99.84% |
| YTD | -23.08% |
| 2023 | -57.52% |
| 2022 | -87.65% |
| 2021 | -45.54% |
| 2020 | -75.93% |
| 2019 | -54.18% |
Loading social stream, please wait...